drugset / Trial / NCT01613053

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

NCT01613053

Expanded access No longer available Novartis Pharmaceuticals

Summary

Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 800 mg